RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
35 hedge funds and large institutions have $11.9M invested in RVL Pharmaceuticals plc Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 12 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
18% less capital invested
Capital invested by funds: $14.5M → $11.9M (-$2.67M)
24% less funds holding
Funds holding: 46 → 35 (-11)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rovida Advisors
Fort Lauderdale,
Florida
|
+$885K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$61K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$59K |
| 4 |
NFG
Nations Financial Group
Cedar Rapids,
Iowa
|
+$42K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$33.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.02M |
| 2 |
Morgan Stanley
New York
|
-$826K |
| 3 |
Squarepoint
New York
|
-$243K |
| 4 |
Renaissance Technologies
New York
|
-$188K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$187K |
RVLP Hedge Fund Activity: Q3 2021 in Review
35 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q3 2021, worth a combined $11.9M — down 18% from $14.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RVLP and 1 opened new positions — a net loss of 11 holders — while 12 trimmed existing stakes and 12 added.
The largest buyer was Rovida Advisors, adding an estimated $885K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $1.02M sold.
- 35 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q3 2021, down from 46 in Q2 2021.
- Funds reported $11.9M of RVL Pharmaceuticals plc Ordinary Shares stock for Q3 2021, down 18% quarter-over-quarter.
- 1 fund opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q3 2021 and 12 closed out, a net change of -11 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q3 2021 was Rovida Advisors, an estimated $885K added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q3 2021 was Jacobs Levy Equity Management, an estimated $1.02M sold.
Based on aggregated 13F filings for Q3 2021.